{"id":19169,"date":"2021-12-06T17:51:54","date_gmt":"2021-12-06T16:51:54","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=19169"},"modified":"2021-12-06T17:51:58","modified_gmt":"2021-12-06T16:51:58","slug":"the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/","title":{"rendered":"The Infectious Diseases Society of America &#8220;Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections&#8221;, Version 2.0"},"content":{"rendered":"\n<p>Published by <a href=\"https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance-2.0\/\" target=\"_blank\" rel=\"noreferrer noopener\">IDSA<\/a>, on 22 November 2021<\/p>\n\n\n\n<p>A focus on&nbsp;<strong>AmpC \u03b2-lactamase-Producing Enterobacterales<\/strong>,&nbsp;<strong>Carbapenem-Resistant&nbsp;<em>Acinetobacter baumannii<\/em><\/strong>, and&nbsp;<strong><em>Stenotrophomonas maltophilia<\/em><\/strong>&nbsp;Infections<\/p>\n\n\n\n<p>Pranita D. Tamma*, Samuel L. Aitken, Robert A. Bonomo, Amy J. Mathers, David van Duin, Cornelius J. Clancy<\/p>\n\n\n\n<p><em>*Corresponding Author<\/em><\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/\" target=\"_blank\" rel=\"noreferrer noopener\">AMR Guidance 1.0: ESBL-E, CRE, and\u00a0<em>Pseudomonas aeruginosa<\/em>\u00a0with Difficult-to-Treat Resistance<\/a><\/strong><\/p>\n\n\n\n<ul><li><a href=\"https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance-2.0\/#toc-0\" target=\"_blank\" rel=\"noreferrer noopener\">Abstract<\/a><\/li><li><a href=\"https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance-2.0\/#toc-1\" target=\"_blank\" rel=\"noreferrer noopener\">Introduction<\/a><\/li><li><a href=\"https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance-2.0\/#toc-2\" target=\"_blank\" rel=\"noreferrer noopener\">Table 1.\u00a0 Suggested dosing of antibiotics for the treatment of infections caused by antimicrobial-resistant organisms<\/a><\/li><li><a href=\"https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance-2.0\/#toc-3\" target=\"_blank\" rel=\"noreferrer noopener\">Methodology<\/a><\/li><li><a href=\"https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance-2.0\/#toc-4\" target=\"_blank\" rel=\"noreferrer noopener\">General Management Recommendations<\/a><\/li><li><a href=\"https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance-2.0\/#toc-5\" target=\"_blank\" rel=\"noreferrer noopener\">AmpC \u03b2-Lactamase-Producing Enterobacterales<\/a><\/li><li><a href=\"https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance-2.0\/#toc-6\" target=\"_blank\" rel=\"noreferrer noopener\">Carbapenem-Resistant Acinetobacter baumannii<\/a><\/li><li><a href=\"https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance-2.0\/#toc-7\" target=\"_blank\" rel=\"noreferrer noopener\">Stenotrophomonas maltophilia<\/a><\/li><li><a href=\"https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance-2.0\/#toc-8\" target=\"_blank\" rel=\"noreferrer noopener\">Notes<\/a><\/li><li><a href=\"https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance-2.0\/#toc-9\" target=\"_blank\" rel=\"noreferrer noopener\">References<\/a><\/li><\/ul>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Published by IDSA, on 22 November 2021 A focus on&nbsp;AmpC \u03b2-lactamase-Producing Enterobacterales,&nbsp;Carbapenem-Resistant&nbsp;Acinetobacter baumannii, and&nbsp;Stenotrophomonas maltophilia&nbsp;Infections Pranita D. Tamma*, Samuel L. Aitken, Robert A. Bonomo, Amy J. Mathers, David van Duin, Cornelius J. Clancy *Corresponding Author AMR Guidance 1.0: ESBL-E, CRE, and\u00a0Pseudomonas aeruginosa\u00a0with Difficult-to-Treat Resistance Abstract Introduction Table 1.\u00a0 Suggested dosing of antibiotics for the treatment [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":19179,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[56,62],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Infectious Diseases Society of America &quot;Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections&quot;, Version 2.0 - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Infectious Diseases Society of America &quot;Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections&quot;, Version 2.0 - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-06T16:51:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-06T16:51:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Livre-ouvert.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"919\" \/>\n\t<meta property=\"og:image:height\" content=\"561\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"The Infectious Diseases Society of America &#8220;Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections&#8221;, Version 2.0\",\"datePublished\":\"2021-12-06T16:51:54+00:00\",\"dateModified\":\"2021-12-06T16:51:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/\"},\"wordCount\":98,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Livre-ouvert.jpg\",\"articleSection\":[\"Practical info &amp; communications\",\"Reviews, reports and recommendations\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/\",\"name\":\"The Infectious Diseases Society of America \\\"Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections\\\", Version 2.0 - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Livre-ouvert.jpg\",\"datePublished\":\"2021-12-06T16:51:54+00:00\",\"dateModified\":\"2021-12-06T16:51:58+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Livre-ouvert.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Livre-ouvert.jpg\",\"width\":919,\"height\":561,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The Infectious Diseases Society of America &#8220;Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections&#8221;, Version 2.0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Infectious Diseases Society of America \"Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections\", Version 2.0 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/","og_locale":"en_GB","og_type":"article","og_title":"The Infectious Diseases Society of America \"Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections\", Version 2.0 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2021-12-06T16:51:54+00:00","article_modified_time":"2021-12-06T16:51:58+00:00","og_image":[{"width":919,"height":561,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Livre-ouvert.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"The Infectious Diseases Society of America &#8220;Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections&#8221;, Version 2.0","datePublished":"2021-12-06T16:51:54+00:00","dateModified":"2021-12-06T16:51:58+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/"},"wordCount":98,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Livre-ouvert.jpg","articleSection":["Practical info &amp; communications","Reviews, reports and recommendations"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/","name":"The Infectious Diseases Society of America \"Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections\", Version 2.0 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Livre-ouvert.jpg","datePublished":"2021-12-06T16:51:54+00:00","dateModified":"2021-12-06T16:51:58+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Livre-ouvert.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Livre-ouvert.jpg","width":919,"height":561,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/the-infectious-diseases-society-of-america-guidance-on-the-treatment-of-antimicrobial-resistant-gram-negative-infections-version-2-0\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"The Infectious Diseases Society of America &#8220;Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections&#8221;, Version 2.0"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-10 22:03:53","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/19169"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=19169"}],"version-history":[{"count":8,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/19169\/revisions"}],"predecessor-version":[{"id":19189,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/19169\/revisions\/19189"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/19179"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=19169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=19169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=19169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}